The estimated Net Worth of Holdings A/S Novo is at least 350 百万$ dollars as of 21 March 2024. Holdings Novo owns over 465,021 units of Galecto stock worth over 33,456,000$ and over the last 11 years Holdings sold GLTO stock worth over 316,438,455$.
Sign up
Holdings Novo GLTO stock SEC Form 4 insiders trading
Holdings has made over 60 trades of the Galecto stock since 2014, according to the Form 4 filled with the SEC. Most recently Holdings sold 465,021 units of GLTO stock worth 348,766$ on 21 March 2024.
The largest trade Holdings's ever made was selling 3,610,487 units of Galecto stock on 14 December 2016 worth over 17,583,072$. On average, Holdings trades about 625,876 units every 58 days since 2014. As of 21 March 2024 Holdings still owns at least 2,550,000 units of Galecto stock.
You can see the complete history of Holdings Novo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Holdings Novo's mailing address?
Holdings's mailing address filed with the SEC is TUBORG HAVNEVEJ 19, , HELLERUP, G7, 2900.
Insiders trading at Galecto
Over the last 4 years, insiders at Galecto have traded over 2,298,261$ worth of Galecto stock and bought 1,911,769 units worth 28,139,830$ . The most active insiders traders include Holdings A/S Novo、Chau Quang Khuong、Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of 2,037,418$. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth 617,010$.
What does Galecto do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
What does Galecto's logo look like?
Complete history of Holdings Novo stock trades at Akebia Therapeutics、AnaptysBio Inc、Apollo Endosurgery Inc、Corvus Pharmaceuticals Inc、Flexion Therapeutics Inc、HTG Molecular Diagnostics Inc、Inogen Inc、iRhythm Technologies Inc、KalVista Pharmaceuticals Inc、Otonomy Inc、Reata Pharmaceuticals Inc、Nevro Corp、Entasis Therapeutics Inc、Milestone Pharmaceuticals Inc、Morphic Inc、Mirum Pharmaceuticals Inc、Galera Therapeutics Inc、Nkarta、Inozyme Pharma、Checkmate Pharmaceuticals、Harmony Biosciences、Spruce Biosciences、Eargo、Praxis Precision Medicines、Aligos Therapeutics、Galecto
Galecto executives and stock owners
Galecto executives and other stock owners filed with the SEC include:
-
Dr. Hans T. Schambye,
Co-Founder, Pres, CEO & Director -
Prof. Bertil Lindmark M.D., Ph.D.,
Chief Medical Officer -
Anders Pedersen,
Chief Operating Officer -
Dr. Stephanie Oestreich Ph.D.,
Chief Bus. Officer -
Garrett Winslow,
Sr. VP & Gen. Counsel -
Jonathan P. Freve CPA, CPA,
Chief Financial Officer -
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
Co-Founder & Member of the Clinical Advisory Board - IPF -
Dr. Hakon Leffler,
Co-Founder -
Ulf J. Nilsson,
Co-Founder -
Advisors Llc Orbi Med Genes...,
-
Holdings A/S Novo,
10% owner -
Carl Goldfischer,
-
Anders Pedersen,
Chief Operating Officer -
Hans T. Schambye,
Chief Executive Officer -
Stephan Christgau,
Director -
Advisors Llc Orbi Med Advis...,
-
Bertil Lindmark,
Chief Medical Officer -
Jonathan Freve,
Chief Financial Officer -
Chau Quang Khuong,
Director -
Stephanie Oestreich,
Chief Business Officer -
Jayson Donald Alexander Dallas,
-
Amit Munshi,
-
Anne Prener,
-
David Shapiro,
-
Garrett Winslow,
General Counsel